Hubungan Gambaran Klinis dan Laboratorium Hematologis antara Leukemia Granulositik Kronik Ph (+)/BCR-ABL (+) dengan Bentuk Kelainan Ph/BCR-ABL Lainnya

Rajabto, Wulyo; Harryanto, A.; Tadjoedin, Hilman; Harimurti, Kuntjoro

doi:10.7454/jpdi.v5i1.167

Cited by 3 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[2] Dan penelitian di RSUPN Dr. Cipto Mangunkusumo. [12] Usia rata-rata terdiagnosa adalah pada saat usia 34 tahun dengan usia paling muda yaitu pada usia 9 tahun dan paling tinggi usia 69 tahun. Hasil ini sejalan dengan penelitian di India.…”

Section: Komsumsi Obat Hasilunclassified

See 1 more Smart Citation

Studi Epidemiologi Penderita Leukemia Granulositik Kronis pada Komunitas ELGEKA di Jawa Barat

Hidayatullah

Sumantri

2022

JRK

View full text Add to dashboard Cite

Abstract. This research is a descriptive observational study, with a cross sectional research design. The number of subjects in this study was 63 people. The selection of subjects using non-probability purposive sampling techniques or research subjects met the inclusion criteria, using the Slovin formula. Data analysis using the SPSS statistical application. The characteristics to be described include domicile, age, sex, occupation, race, age at diagnosis, latest education, medication, initial and final BCR-ABL values, leukocytes, platelets and hemoglobin. The results showed the highest prevalence was in Bandung (20%), with an age range of 30-39 years (38.1%), suffered mostly by women (55.6%), most of them were private employees (28.6%), people with Sundanese race (68.3%), the average age of diagnosis was 34 years, the latest education was higher education graduate (57.1%), the most drug used was imatinib (81.3%), the initial dominant BCR-ABL value was > 10% and end dominant was < 0.1%, the results of a routine dominant hemoglobin blood test were 8-12 g/dL, the results of dominant leukocytes were 5000-10,000/mm3, and the yield of dominant platelets was 150,000 to 400,000 mm3. Abstrak. Penelitian ini bertujuan untuk mendiskripsikan karakteristik penderita leukemia granulositik kronis pada komunitas ELGEKA Jawa Barat. Penelitian ini adalah sebuah penelitian deskriptif observasional, dengan desain penelitian cross sectional. Jumlah Subjek dalam penelitian ini adalah 63 orang. Pemilihan subjek dengan teknik non probability purposive sampling atau subjek penilitian memenuhi kriteria inklusi, menggunakan rumus slovin. Analisis data menggunakan aplikasi statistik SPSS. Karakteristik yang akan digambarkan meliputi domisili, usia, jenis kelamin, pekerjaan, ras, usia diagnosis, pendidikan terakhir, pengobatan, nilai BCR-ABL awal dn akhir, leukosit, trombosit dan hemoglobin. Hasil menunjukan bahwa pravelensi tertinggi berada di Kota Bandung (20%), dengan rentang usia 30-39 tahun (38,1%), jenis kelamin terbanyak wanita (55,6%), pekerjaan terbanyak pegawai swasta (28,6%), Ras terbanyak sunda (68,3%), usia rata-rata diagnosis 34 tahun, pendidikan terakhir perguruan tinggi (57,1%), penggunaan obat terbanyak imatinib (81.3%), nilai BCR-ABL awal dominan >10% dan akhir dominan <0,1%, hasil pemeriksaan darah rutin dominan hemoglobin 8-12g/dL, leukosit dominan dengan hasil 5000-10.000/mm3 dan trombosit dominan dengan hasil 150.000-400.000 mm3.

show abstract

Section: Komsumsi Obat Hasilunclassified

“…[2] Pada penelitian Wulyo Rajabto tahun 2018 hasil leukosit >100.000/uL dan trombosit >450.000 mm3. [12]…”

Section: Komsumsi Obat Hasilunclassified

Studi Epidemiologi Penderita Leukemia Granulositik Kronis pada Komunitas ELGEKA di Jawa Barat

Hidayatullah

Sumantri

2022

JRK

View full text Add to dashboard Cite

show abstract

Mutation Analysis of ABL1 Gene and its Relation to the Achievement of Major Molecular Response in Indonesian Chronic Myeloid Leukemia Patients

Widyastuti

Louisa

Rinaldi

et al. 2020

CPPM

View full text Add to dashboard Cite

Background: Imatinib mesylate is the first tyrosine kinase inhibitor approved for chronic myeloid leukemia (CML) therapy. Imatinib is an effective drug. However, previous studies have shown that about 20-30% of patients eventually would develop resistance to imatinib. Approximately 40% of imatinib resistance is associated with BCRABL kinase domain mutation. One of the most common and serious variations account for imatinib response is T315I of ABL1 gene. Objective: The study aimed to examine the association of T315I mutation with the ABL1 gene and its relation to major molecular response (MMR) achievement in CML patients. This study also examined other mutations adjacent to T315I, i.e., F311I, F317L, and different possible variations in the ABL1 gene. Methods: This was a cross-sectional study on Indonesian CML patients in chronic phase. We analyzed 120 blood samples from patients in chronic phase who have received imatinib mesylate (IM) for ≥12 months. Results: There were no T315I, F311I, and F317L mutations found in this study. However, we found another variation, which was 36 substitutions from A to G at position 163816 of ABL1 gene (according to NG_012034.1). Conclusions: We found no T315I, F311I, and F317L mutations in this study. Our findings suggest that there might be other factors that influenced the MMR achievement in our study patients. However, there were 36 substitutions from A to G at position 163.816 (according to NG_012034.1) that needed further examination to explore the significance of this mutation in clinical practice.

show abstract

Asymptomatic chronic-phase chronic myeloid leukemia BCR-ABL. (+) without splenomegaly: A case report

Rajabto

Angkasa

2022

Niger J Clin Pract

View full text Add to dashboard Cite

Hubungan Gambaran Klinis dan Laboratorium Hematologis antara Leukemia Granulositik Kronik Ph (+)/BCR-ABL (+) dengan Bentuk Kelainan Ph/BCR-ABL Lainnya

Cited by 3 publications

References 5 publications

Studi Epidemiologi Penderita Leukemia Granulositik Kronis pada Komunitas ELGEKA di Jawa Barat

Studi Epidemiologi Penderita Leukemia Granulositik Kronis pada Komunitas ELGEKA di Jawa Barat

Mutation Analysis of ABL1 Gene and its Relation to the Achievement of Major Molecular Response in Indonesian Chronic Myeloid Leukemia Patients

Asymptomatic chronic-phase chronic myeloid leukemia BCR-ABL. (+) without splenomegaly: A case report

Contact Info

Product

Resources

About